Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Circ Cardiovasc Interv ; 12(3): e007546, 2019 03.
Article in English | MEDLINE | ID: mdl-30871358

ABSTRACT

BACKGROUND: Stroke remains one of the most devastating complications of transcatheter aortic valve implantation (TAVI). The aim of this study was to identify the incidence, timing, temporal trends, and predictors of stroke after TAVI and evaluate the outcomes of patients with stroke. METHODS AND RESULTS: The CENTER-Collaboration is an international collaboration consisting of 3 national registries and 7 local registries or prospective clinical trials, selected through a systematic review. Accordingly, a total of 10 982 patients undergoing transfemoral TAVI between 2007 and 2018 were included in the current patient-level pooled analyses. A total of 261 patients (2.4%) experienced stroke during the first month after TAVI. The median time between TAVI and stroke was 1 day (interquartile range, 0-6 days). The stroke rate was comparable in procedures performed in the early years of TAVI (2007-2012) to those in the more recent years of TAVI (2013-2018; both 2.4%; P=1.0). Independent predictors of stroke at 30 days were a history of cerebrovascular events (odds ratio, 2.2; 95% CI, 1.4-3.6; P=0.0012) and a glomerular filtration rate of <30 mL/min per 1.73 m2 (odds ratio, 1.7; 95% CI, 1.0-2.8; P=0.05). Stroke occurring within the first 30 days after TAVI was associated with a 6-fold increase of 30-day mortality (odds ratio, 6.0; 95% CI, 4.4-8.1; P<0.001). Moreover, patients with stroke more frequently had documented new-onset atrial fibrillation (16% versus 3%; P<0.001) and major or life-threatening bleedings (12% versus 7%; P=0.002) at 30-day follow-up. CONCLUSIONS: In this large, global, patient-level analysis, the incidence of stroke after transfemoral TAVI was 2.4%. Prior cerebrovascular events and a low glomerular filtration rate independently predicted the occurrence of stroke after TAVI. The occurrence of stroke after TAVI was associated with a strikingly 6-fold increase of 30-day mortality; additionally, there was a 5-fold higher rate of new-onset atrial fibrillation in patients with stroke. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03588247.


Subject(s)
Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Catheterization, Peripheral/adverse effects , Femoral Artery , Stroke/epidemiology , Transcatheter Aortic Valve Replacement/adverse effects , Aged , Aged, 80 and over , Aortic Valve Stenosis/mortality , Catheterization, Peripheral/mortality , Clinical Trials as Topic , Female , Humans , Incidence , Male , Punctures , Registries , Risk Assessment , Risk Factors , Stroke/diagnosis , Stroke/mortality , Time Factors , Transcatheter Aortic Valve Replacement/mortality , Treatment Outcome
3.
Ital J Pediatr ; 44(1): 34, 2018 Mar 09.
Article in English | MEDLINE | ID: mdl-29523172

ABSTRACT

BACKGROUND: Since 2010, array-CGH (aCGH) has been the first-tier test in the diagnostic approach of children with neurodevelopmental disorders (NDD) or multiple congenital anomalies (MCA) of unknown origin. Its broad application led to the detection of numerous variants of uncertain clinical significance (VOUS). How to appropriately interpret aCGH results represents a challenge for the clinician. METHOD: We present a retrospective study on 293 patients with age range 1 month - 29 years (median 7 years) with NDD and/or MCA and/or dysmorphisms, investigated through aCGH between 2005 and 2016. The aim of the study was to analyze clinical and molecular cytogenetic data in order to identify what elements could be useful to interpret unknown or poorly described aberrations. Comparison of phenotype and cytogenetic characteristics through univariate analysis and multivariate logistic regression was performed. RESULTS: Copy number variations (CNVs) with a frequency < 1% were detected in 225 patients of the total sample, while 68 patients presented only variants with higher frequency (heterozygous deletions or amplification) and were considered to have negative aCGH. Proved pathogenic CNVs were detected in 70 patients (20.6%). Delayed psychomotor development, intellectual disability, intrauterine growth retardation (IUGR), prematurity, congenital heart disease, cerebral malformations and dysmorphisms correlated to reported pathogenic CNVs. Prematurity, ventricular septal defect and dysmorphisms remained significant predictors of pathogenic CNVs in the multivariate logistic model whereas abnormal EEG and limb dysmorphisms were mainly detected in the group with likely pathogenic VOUS. A flow-chart regarding the care for patients with NDD and/or MCA and/or dysmorphisms and the interpretation of aCGH has been made on the basis of the data inferred from this study and literature. CONCLUSION: Our work contributes to make the investigative process of CNVs more informative and suggests possible directions in aCGH interpretation and phenotype correlation.


Subject(s)
Abnormalities, Multiple/genetics , Comparative Genomic Hybridization/methods , DNA Copy Number Variations , Heart Septal Defects, Ventricular/genetics , Infant, Premature, Diseases/genetics , Muscular Atrophy/genetics , Neurodevelopmental Disorders/genetics , Abnormalities, Multiple/diagnosis , Adolescent , Adult , Child , Child, Preschool , Facies , Female , Genetic Testing , Heart Septal Defects, Ventricular/diagnosis , Humans , Infant , Infant, Newborn , Infant, Premature, Diseases/diagnosis , Male , Muscular Atrophy/diagnosis , Neurodevelopmental Disorders/diagnosis , Phenotype , Retrospective Studies , Young Adult
4.
J Cutan Pathol ; 43(12): 1197-1202, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27596542

ABSTRACT

Birt-Hogg-Dubé syndrome (BHDS), first described in 1977, is a rare autosomal dominant disorder, linked to germline mutations in the FLCN (folliculin) gene. Patients may present with different skin tumors, pulmonary cysts with recurrent spontaneous pneumothorax, and renal cancers, but it has also been estimated that about 25% of carriers older than 20 years do not show skin involvement. So far, besides the triad of skin lesions of the original description (fibrofolliculomas, trichodischomas and acrochordons), a wide range of neoplastic and non-neoplastic skin conditions have been reported, i.e. melanomas, trichoblastoma, neural- and connective tissue tumors, lipomas, angiolipomas and focal cutaneous mucinosis. We describe a patient with BHDS developing multiple skin angiomatous lesions with prominent signet-ring features, an association never reported so far. As renal carcinomas represent the most threatening complication in BHDS and the identification of the patients with BHDS is mainly based on the clinical and histopathologic identification of the diagnostic skin lesions, the role of the dermatologist can be crucial in the prevention and early detection of a potentially aggressive renal cancer.


Subject(s)
Birt-Hogg-Dube Syndrome/pathology , Hemangioma/genetics , Skin Neoplasms/genetics , Adult , Female , Humans , Mutation , Proto-Oncogene Proteins/genetics , Tumor Suppressor Proteins/genetics
5.
Cancer Lett ; 378(2): 120-30, 2016 08 10.
Article in English | MEDLINE | ID: mdl-27181379

ABSTRACT

BAP1 germline mutations predispose to a cancer predisposition syndrome that includes mesothelioma, cutaneous melanoma, uveal melanoma and other cancers. This co-occurrence suggests that these tumors share a common carcinogenic pathway. To evaluate this hypothesis, we studied 40 Italian families with mesothelioma and/or melanoma. The probands were sequenced for BAP1 and for the most common melanoma predisposition genes (i.e. CDKN2A, CDK4, TERT, MITF and POT1) to investigate if these genes may also confer susceptibility to mesothelioma. In two out of six families with both mesothelioma and melanoma we identified either a germline nonsense mutation (c.1153C > T, p.Arg385*) in BAP1 or a recurrent pathogenic germline mutation (c.301G > T, p.Gly101Trp) in CDKN2A. Our study suggests that CDKN2A, in addition to BAP1, could be involved in the melanoma and mesothelioma susceptibility, leading to the rare familial cancer syndromes. It also suggests that these tumors share key steps that drive carcinogenesis and that other genes may be involved in inherited predisposition to malignant mesothelioma and melanoma.


Subject(s)
Biomarkers, Tumor/genetics , Codon, Nonsense , Cyclin-Dependent Kinase Inhibitor p18/genetics , Germ-Line Mutation , Melanoma/genetics , Mesothelioma/genetics , Skin Neoplasms/genetics , Tumor Suppressor Proteins/genetics , Ubiquitin Thiolesterase/genetics , Adolescent , Adult , Aged , Biomarkers, Tumor/analysis , Cyclin-Dependent Kinase Inhibitor p16 , Cyclin-Dependent Kinase Inhibitor p18/analysis , DNA Mutational Analysis , Databases, Factual , Female , Genetic Association Studies , Genetic Predisposition to Disease , Heredity , Humans , Immunohistochemistry , Italy , Male , Melanoma/chemistry , Melanoma/pathology , Mesothelioma/chemistry , Mesothelioma/pathology , Middle Aged , Pedigree , Phenotype , Risk Factors , Skin Neoplasms/chemistry , Skin Neoplasms/pathology , Tumor Suppressor Proteins/analysis , Ubiquitin Thiolesterase/analysis , Young Adult
7.
Mol Syndromol ; 2(1): 35-44, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22582037

ABSTRACT

22q11.2 deletion syndrome is mainly characterized by conotruncal congenital heart defects, velopharyngeal insufficiency, hypocalcemia and a characteristic craniofacial appearance. The etiology in the majority of patients is a 3-Mb recurrent deletion in region 22q11.2. Nevertheless, recently some cases of infrequent deletions with various sizes have been reported with a different phenotype. We report on a patient with congenital heart disease (truncus arteriosus type 2) in whom a de novo 1.3-Mb 22q11.2 deletion was detected by array comparative genomic hybridization. The deletion described corresponds to an atypical and distal deletion which spans low copy repeat (LCR) 4 and is associated with breakpoint sites that do not correspond to known LCRs of 22q11.2. We examine the clinical phenotype of our case and compare our findings with those published in the literature. The most prevalent clinical features in this type of deletion are a history of prematurity, pre-natal and post-natal growth retardation, slight facial dysmorphic features, microcephaly and developmental delay, with a speech defect in particular. These are clearly different from those found in the classic 22q11.2 deletion syndrome, and we believe that the main differential diagnosis should be with Silver-Russel syndrome. In our case we observe the cardiac phenotype with truncus arteriosus communis usually seen in the classic 22q11.2 deletion syndrome, and so far associated with the TBX1 gene. Significantly, however, TBX1 is not included in our patient's deletion. The possible roles of a position effect or other genes are discussed.

8.
Am J Med Genet A ; 149A(10): 2258-64, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19764019

ABSTRACT

Mandibuloacral dysplasia type A (MADA) is characterized by growth retardation, postnatal onset of craniofacial anomalies with mandibular hypoplasia, progressive acral osteolysis, and skin changes including mottled pigmentation, skin atrophy, and lipodystrophy. Owing to its slowly progressive course, the syndrome has been recognized in adults, and pediatric case reports are scarce. We present the clinical case of two children in whom the diagnosis of MADA was made at an unusually early age. A 5-year-old boy presented with ocular proptosis, thin nose, and short and bulbous distal phalanges of fingers. A 4-year-old girl presented with round face and chubby cheeks, thin nose, bulbous fingertips, and type A lipodystrophy. In both, a skeletal survey showed wormian bones, thin clavicles, short distal phalanges of fingers and toes with acro-osteolysis. Both children were found to be homozygous for the recurrent missense mutation, c.1580G>A, (p.R527H) in exon 9 of the LMNA gene. Thus, the phenotype of MADA can be manifest in preschool age; diagnosis may be suggested by short and bulbous fingertips, facial features, and lipodystrophy, supported by the finding of acral osteolysis, and confirmed by mutation analysis.


Subject(s)
Bone Diseases, Developmental/congenital , Craniofacial Abnormalities/diagnosis , Mandibular Diseases/congenital , Age of Onset , Bone Diseases, Developmental/diagnosis , Bone Diseases, Developmental/epidemiology , Child, Preschool , Craniofacial Abnormalities/epidemiology , Female , Humans , Lipodystrophy/complications , Lipodystrophy/congenital , Lipodystrophy/diagnosis , Male , Mandibular Diseases/complications , Mandibular Diseases/diagnosis , Mandibular Diseases/epidemiology
9.
Neuropediatrics ; 40(6): 284-6, 2009 Dec.
Article in English | MEDLINE | ID: mdl-20446223

ABSTRACT

Polyposis of the gallbladder is rare during childhood. This condition can be associated with three other conditions: metachromatic leukodystrophy, Peutz-Jeghers' syndrome, and pancreaticobiliary maljunction. We report the case of a child with hemobilia in metachromatic leukodystrophy, which rendered cholecystectomy necessary. Macroscopically, the gallbladder measured 4.6 cm in length and showed an opaque serous surface and focal brown petechiae. Moreover, a yellow polypoid lesion of 2 cm in diameter and a diffuse thickening of the fundus wall were observed. Many reports describe the importance of the association of gallbladder papillomatosis with metachromatic leukodystrophy, but only three cases presented with massive intestinal bleeding, such as our young patient had. It is thus imperative that this life-threatening condition should be well known.


Subject(s)
Gallbladder Neoplasms/complications , Hemobilia/complications , Leukodystrophy, Metachromatic/complications , Leukodystrophy, Metachromatic/pathology , Papilloma/complications , Child, Preschool , Gallbladder Neoplasms/pathology , Hemobilia/pathology , Humans , Male , Papilloma/pathology
10.
Minerva Chir ; 59(3): 233-41, 2004 Jun.
Article in Italian | MEDLINE | ID: mdl-15252388

ABSTRACT

AIM: Radical peritonectomy followed by intraperitoneal early chemotherapy and systemic chemotherapy is the treatment of choice of stage II C and III ovarian cancer, due to the low 5-years survival rate (20%) of stage III and IV. METHODS: The authors present a 5-years experience in 37 patients affected by stage II C and III ovarian cancer treated by Sugarbaker's radical peritonectomy with some surgical technical differences. Intraperitoneal chemotherapy with adriamycin and cisplatin is started and followed after 25 days by a systemic chemotherapy with taxol and carboplatin. A 6-months second-look is performed. RESULTS: All the patients have been treated with radical peritonectomy with tumoral residual lesser than 2.5 mm; we performed 4 minor hepatectomies, 5 radical cystectomies, 35 resections of rectum and sigmoid colon with hysterectomies, bilateral salpingo-oophorectomies and pelviperitonectomies, 14 right hemicolectomies. We had no postoperative mortality, but we recorded a 40% minor morbidity rate. During the second look we found 7 recurrences (18%), 6 lesser than 6 mm, often located on the mesentery and treated with radical resections. The follow-up range is 2-60 months, 27 patients are still alive. Actually, 22 patients (80% of live patients) are in good health and disease free. CONCLUSION: Radical surgery associated with early postoperative chemotherapy followed by systemic chemotherapy in the treatment of ovarian cancer makes it possible to achieve the best survival results and long periods of disease free.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/pathology , Carcinoma/surgery , Ovarian Neoplasms/pathology , Ovarian Neoplasms/surgery , Peritoneum/surgery , Carboplatin/administration & dosage , Carcinoma/drug therapy , Chemotherapy, Adjuvant/methods , Cisplatin/administration & dosage , Doxorubicin/administration & dosage , Female , Humans , Infusions, Parenteral , Neoplasm Recurrence, Local/surgery , Neoplasm Staging , Ovarian Neoplasms/drug therapy , Paclitaxel/administration & dosage , Retrospective Studies , Second-Look Surgery , Treatment Outcome
11.
J Lab Clin Med ; 89(2): 409-13, 1977 Feb.
Article in English | MEDLINE | ID: mdl-833476

ABSTRACT

The Kalmedic D-3 Fragiligraph was used to obtain both cumulative and derivative osmotic fragility data. Several instrumental modifications and several procedural changes combined to make the data more reproducible and more easily obtained. An analytical expression employing but two parameters was found to give excellent fits for the cumulative data, and when differentiated, reproduced the experimental derivative data equally well. The curve fitting procedure used is given in detail. Data obtained on a limited number of subjects with beta-thalassemia or multiple sclerosis are presented. The interpretation of these data by techniques common to the literature is compared with the procedure developed in this paper.


Subject(s)
Multiple Sclerosis/blood , Osmotic Fragility , Thalassemia/blood , Hemolysis , Humans , Methods
SELECTION OF CITATIONS
SEARCH DETAIL
...